Sunshine Biopharma Enters Canadian Generic Gabapentin Market for Neuropathic Pain

Sunshine Biopharma has launched generic Gabapentin in Canada for treating neuropathic pain and epilepsy. The global Gabapentin market is projected to reach $3.07 billion by 2030, with Canada's generic drug market expected to grow from $9.4 billion to $19.2 billion by 2032. The company's move aims to strengthen its presence in Canada and capitalize on the growing demand for generic drugs.

Sunshine Biopharma Inc. (NASDAQ: SBFM) has expanded its pharmaceutical portfolio by launching a generic version of Gabapentin in Canada. This move comes as the company aims to strengthen its presence in the Canadian market and capitalize on the growing demand for generic drugs.

Gabapentin, an anticonvulsant medication used to treat neuropathic pain and epilepsy, is now available in Canada through Nora Pharma Inc., Sunshine Biopharma's wholly-owned subsidiary. The generic drug is available in strengths of 100 mg, 300 mg, and 400 mg, packaged in bottles of 500 capsules. The capsule format is preferred due to its ease of administration, particularly in children and the elderly [1].

The global Gabapentin market was valued at $1.92 billion in 2024 and is projected to reach $3.07 billion by 2030, driven by increasing prevalence of neurological disorders, expanding applications beyond neuropathic pain and epilepsy, a shift away from opioids for pain management, and an aging population [1]. Canada represents approximately 1.2% of the global pharmaceutical market for Gabapentin, but it is ranked as the eighth-largest pharmaceutical market in the world [1].

Sunshine Biopharma's move into the Canadian market aligns with its strategic plan to fortify its presence in the dynamic generic drugs market. The company's CEO, Dr. Steve Slilaty, stated, "We are committed to fortifying our presence in Canada's dynamic $9.4 billion generic drugs market, which is forecasted to nearly double to $19.2 billion by 2032. By steadily expanding our product offerings, investing in research, and maintaining the highest standards of quality, we aim to make a meaningful difference in the lives of patients" [1].

Sunshine Biopharma currently has 71 generic prescription drugs on the market in Canada and plans to launch more than 12 additional drugs in the remainder of 2025. Among these is NIOPEG®, a biosimilar of NEULASTA®, which is indicated to decrease the incidence of infection in patients with non-myeloid malignancies receiving anti-neoplastic therapy. The company is also conducting a proprietary drug development program that includes K1.1 mRNA for liver cancer and PLpro protease inhibitor for SARS Coronavirus infections [1].

This launch is part of Sunshine Biopharma's broader strategy to grow its generic drug portfolio and capitalize on the increasing demand for affordable medicines. The company's forward-looking statements highlight the potential risks and uncertainties associated with its drug development activities, financial performance, and future growth [1].

References:
[1] https://www.morningstar.com/news/accesswire/1038140msn/sunshine-biopharma-launches-generic-gabapentin-for-neuropathic-pain-in-the-canadian-segment-of-the-global-192-billion-market